Pazopanib HCl has been evaluated across numerous clinical trials spanning Early Phase 1 through Phase 4, with research predominantly focusing on oncologic and vascular conditions such as soft-tissue sarcoma, renal cell carcinoma, non-small cell lung cancer, breast cancer, and hereditary hemorrhagic telangiectasia. These investigations include both completed and actively recruiting protocols supported by academic, governmental, non-profit, and pharmaceutical sponsors.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06239272 | RECRUITING | Adipocytic Neoplasm; Liposarcoma; Atypical Fibroxanthoma; Angiomatoid Fibrous Histiocytoma; Fibrosarcoma NOS; Myxofibrosarcoma; Angiosarcoma; Osteosarcoma, Extraskeletal; Dedifferentiated Liposarcoma; Myxoid Liposarcoma; Pleomorphic Liposarcoma; Myxoid Pleomorphic Liposarcoma; Low Grade Fibromyxoid Sarcoma; Sclerosing Epithelioid Fibrosarcoma; Malignant Tenosynovial Giant Cell Tumor of Soft Tissue; Epithelioid Hemangioendothelioma; Glomus Tumor; Inflammatory Leiomyosarcoma; Leiomyosarcoma; Ossifying Fibromyxoid Tumor, Malignant; Myoepithelioma; Synovial Sarcoma; Epithelioid Sarcoma; Perineurioma, Malignant; Clear Cell Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Granular Cell Tumor, Malignant; Melanotic Malignant Nerve Sheath Tumor; Malignant Peripheral Nerve Sheath Tumor; Perivascular Epithelioid Tumor, Malignant; Intimal Sarcoma; Myoepithelial Carcinoma; Undifferentiated Sarcoma; Pleomorphic Sarcoma, Undifferentiated; Round Cell Sarcoma, Undifferentiated; NTRK-Rearranged Spindle Cell Neoplasm; Phosphaturic Mesenchymal Tumor, Malignant; Round Cell Sarcoma; Well Differentiated Liposarcoma; Giant Cell Tumor of Soft Parts NOS; Low Grade Myofibroblastic Sarcoma; Dermatofibrosarcoma Protuberans, Fibrosarcomatous |
St. Jude Children's Research Hospital |
2024-03-27 | PHASE1; PHASE2 |
| NCT07444619 | RECRUITING | Soft Tissue Sarcomas |
M.D. Anderson Cancer Center |
2026-06-12 | PHASE1 |
| NCT06726421 | RECRUITING | Renal Cell Carcinoma (Kidney Cancer); Kidney Cancer Metastatic; Renal Cell Carcinoma Metastatic |
Sun Yat-sen University |
2024-09-18 | PHASE3 |
| NCT04199026 | RECRUITING | Metastatic Sarcoma; Recurrent Sarcoma; Resectable Sarcoma |
M.D. Anderson Cancer Center |
2025-02-25 | |
| NCT01217931 | ACTIVE_NOT_RECRUITING | Kidney Cancer |
M.D. Anderson Cancer Center |
2011-01-19 | PHASE2 |
| NCT02029001 | RECRUITING | Malignant Solid Neoplasms |
Centre Leon Berard |
2014-03 | PHASE2 |
| NCT06263231 | RECRUITING | Sarcoma,Soft Tissue |
Intensity Therapeutics, Inc. |
2024-06-28 | PHASE3 |
| NCT02331498 | ACTIVE_NOT_RECRUITING | Glioblastoma Multiforme |
Centre Antoine Lacassagne |
2015-06 | PHASE1; PHASE2 |
| NCT05180695 | ACTIVE_NOT_RECRUITING | Advanced Soft-tissue Sarcoma; Metastatic Soft-tissue Sarcoma |
Centre Leon Berard |
2022-04-15 | PHASE1; PHASE2 |
| NCT05679921 | RECRUITING | Soft Tissue Sarcoma |
Yonsei University |
2024-03-01 | PHASE2 |
| NCT06739395 | RECRUITING | Solid Tumor; Precision Medicine |
Tianjin Medical University Second Hospital |
2024-11-01 | PHASE2 |
| NCT07087158 | RECRUITING | Renal Cell Carcinoma (RCC) |
Imbioray (Hangzhou) Biomedicine Co., Ltd. |
2025-09-08 | PHASE2 |
| NCT03592472 | RECRUITING | Renal Cell Carcinoma |
Xynomic Pharmaceuticals, Inc. |
2018-07-17 | PHASE3 |
| NCT01684397 | ACTIVE_NOT_RECRUITING | Clear Cell Renal Cell Carcinoma; Stage IV Renal Cell Cancer |
Roswell Park Cancer Institute |
2012-11-21 | PHASE1; PHASE2 |
| NCT06816771 | RECRUITING | Rhabdomyosarcoma, Recurrent, Refractory |
Shandong Cancer Hospital and Institute |
2025-02 | PHASE2 |
| NCT06895733 | RECRUITING | Solid Tumor, Adult; Next-generation Sequencing; Precision Medicine |
Tianjin Medical University Second Hospital |
2024-11-27 | PHASE1; PHASE2 |
| NCT03850964 | ACTIVE_NOT_RECRUITING | Hereditary Hemorrhagic Telangiectasia; Epistaxis; Anemia; Nosebleed; HHT |
Cure HHT |
2023-05-08 | PHASE2; PHASE3 |
| NCT05210413 | ACTIVE_NOT_RECRUITING | Refractory or Recurrent Solid Tumor |
University Hospital, Bordeaux |
2022-05-17 | PHASE1; PHASE2 |
| NCT03850730 | UNKNOWN | Hereditary Hemorrhagic Telangiectasia; Epistaxis |
Cure HHT |
2023-07-01 | PHASE1; PHASE2 |
| NCT05949424 | UNKNOWN | Renal Cell Carcinoma; Ovarian Carcinoma; Thyroid Carcinoma; Breast Carcinoma; Endometrium Carcinoma |
University Medical Center Groningen |
2024-05 | PHASE4 |
| NCT04741438 | UNKNOWN | Sarcoma |
Centre Leon Berard |
2021-03-30 | PHASE3 |
| NCT02203760 | ACTIVE_NOT_RECRUITING | Leiomyosarcoma or Carcinosarcoma |
North Eastern German Society of Gynaecological Oncology |
2019-10-16 | PHASE2 |
| NCT05432791 | ACTIVE_NOT_RECRUITING | Locally Advanced Uterine Corpus Leiomyosarcoma; Metastatic Uterine Corpus Leiomyosarcoma; Stage III Uterine Corpus Leiomyosarcoma AJCC v8; Stage IV Uterine Corpus Leiomyosarcoma AJCC v8; Unresectable Uterine Corpus Leiomyosarcoma |
National Cancer Institute (NCI) |
2023-03-30 | PHASE2; PHASE3 |
| NCT01436227 | COMPLETED | Von Hippel-Lindau Syndrome |
M.D. Anderson Cancer Center |
2012-01-17 | PHASE2 |
| NCT01543763 | COMPLETED | Metastatic Solid Tumors |
Pamela Munster |
2012-06-25 | PHASE1 |
| NCT05816642 | UNKNOWN | Metastatic Renal Cell Carcinoma |
RenJi Hospital |
2022-08-01 | |
| NCT03628131 | UNKNOWN | Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor |
Samsung Medical Center |
2018-10 | PHASE1; PHASE2 |
| NCT03850964 | Recruiting | Hereditary Hemorrhagic Telangiectasia|Epistaxis|Anemia|Nosebleed|HHT |
Cure HHT |
2023-05-08 | Phase 2|Phase 3 |
| NCT03660930 | TERMINATED | Advanced Soft Tissue Sarcoma; Locally Advanced Soft Tissue Sarcoma; Metastatic Soft Tissue Sarcoma |
University of Washington |
2019-04-01 | PHASE1; PHASE2 |
| NCT03571438 | UNKNOWN | Kidney Cancer |
University Hospital, Grenoble |
2017-10-16 | |
| NCT03798106 | COMPLETED | Sarcoma |
Yonsei University |
2019-04-10 | PHASE2 |
| NCT02303028 | COMPLETED | Solid Tumors |
The Hospital for Sick Children |
2015-03 | PHASE1; PHASE2 |
| NCT05180695 | Recruiting | Advanced Soft-tissue Sarcoma|Metastatic Soft-tissue Sarcoma |
Centre Leon Berard|Novartis|National Cancer Institute France |
2022-04-15 | Phase 1|Phase 2 |
| NCT02638428 | UNKNOWN | Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor; Relapsed Pediatric AML; Refractory Pediatric AML |
Samsung Medical Center |
2015-12 | PHASE2 |
| NCT01548144 | TERMINATED | Advanced Cancers |
M.D. Anderson Cancer Center |
2012-04 | PHASE1 |
| NCT03200717 | COMPLETED | Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma |
Novartis Pharmaceuticals |
2017-11-14 | PHASE2 |
| NCT03334409 | TERMINATED | Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v7; Unresectable Renal Cell Carcinoma |
Academic and Community Cancer Research United |
2018-02-16 | PHASE2 |
| NCT02960906 | COMPLETED | Clear Cell Metastatic Renal Cell Carcinoma |
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie |
2017-05-31 | PHASE2 |
| NCT01664182 | COMPLETED | Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7 |
National Cancer Institute (NCI) |
2012-08-01 | PHASE2 |
| NCT03735758 | TERMINATED | Soft Tissue Sarcoma Adult |
GWT-TUD GmbH |
2018-11-02 | PHASE4 |
| NCT02959554 | TERMINATED | Metastatic Renal Cell Carcinoma |
AIO-Studien-gGmbH |
2016-12 | PHASE2 |
| NCT01430572 | COMPLETED | Advanced Cancers; Solid Tumors |
M.D. Anderson Cancer Center |
2011-10-07 | PHASE1 |
| NCT01566747 | COMPLETED | Renal Cell Carcinoma |
Cancer Trials Ireland |
2011-03 | PHASE2 |
| NCT01236547 | COMPLETED | Thyroid Gland Anaplastic Carcinoma |
National Cancer Institute (NCI) |
2010-10-28 | PHASE2 |
| NCT02555748 | COMPLETED | Metastatic Renal Cell Cancer |
Institut Claudius Regaud |
2015-11-17 | PHASE4 |
| NCT02342600 | WITHDRAWN | Gastrointestinal Stromal Tumors |
Sarcoma Alliance for Research through Collaboration |
2017-01 | PHASE2 |
| NCT02212015 | TERMINATED | Angiosarcoma |
Heidelberg University |
2014-07 | PHASE2 |
| NCT02193152 | TERMINATED | Carcinoma, Non-Small Cell Lung; Non-Small Cell Lung Cancer; Nonsmall Cell Lung Cancer |
Washington University School of Medicine |
2015-04-27 | PHASE2 |
| NCT02066285 | COMPLETED | Solitary Fibrous Tumor; Extraskeletal Myxoid Chondrosarcoma |
Grupo Espanol de Investigacion en Sarcomas |
2014-06 | PHASE2 |
| NCT01956669 | COMPLETED | Solid Tumours |
Novartis Pharmaceuticals |
2014-10-08 | PHASE2 |
| NCT01532687 | COMPLETED | Adult Alveolar Soft Part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma; Adult Epithelioid Sarcoma; Adult Extraskeletal Myxoid Chondrosarcoma; Adult Extraskeletal Osteosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Peripheral Nerve Sheath Tumor; Adult Rhabdomyosarcoma; Adult Synovial Sarcoma; Adult Undifferentiated Pleomorphic Sarcoma; Malignant Adult Hemangiopericytoma; Recurrent Adult Soft Tissue Sarcoma; Sarcoma; Stage III Adult Soft Tissue Sarcoma AJCC v7; Stage IV Adult Soft Tissue Sarcoma AJCC v7 |
OHSU Knight Cancer Institute |
2012-03-13 | PHASE2 |
| NCT03139331 | COMPLETED | Sarcoma; Refractory Sarcoma |
University of California, San Francisco |
2017-06-06 | PHASE1 |
| NCT01931098 | COMPLETED | Glioblastoma; Glioblastoma Multiforme; Gliosarcoma; Brain Neoplasms; Central Nervous System Neoplasms |
National Cancer Institute (NCI) |
2015-12-10 | PHASE2 |
| NCT01392183 | COMPLETED | Kidney Cancer |
M.D. Anderson Cancer Center |
2012-10-24 | PHASE2 |
| NCT02383251 | COMPLETED | Ovarian Cancer |
ARCAGY/ GINECO GROUP |
2015-06-15 | PHASE2 |
| NCT02348398 | WITHDRAWN | Cervical Cancer |
M.D. Anderson Cancer Center |
2016-08 | PHASE2 |
| NCT02180867 | COMPLETED | Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Fibrosarcoma; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Liver Embryonal Sarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Peripheral Nerve Sheath Tumor; Malignant Skin Granular Cell Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Skin Glomus Tumor; Stage IB Soft Tissue Sarcoma AJCC v7; Stage IIB Soft Tissue Sarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Synovial Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone |
National Cancer Institute (NCI) |
2014-08-12 | PHASE2; PHASE3 |
| NCT02300545 | COMPLETED | Sarcoma, Soft Tissue; Soft Tissue Sarcoma |
Washington University School of Medicine |
2015-04-08 | PHASE2 |
| NCT01402271 | COMPLETED | Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2012-07 | PHASE1; PHASE2 |
| NCT01593748 | COMPLETED | Sarcoma |
Medical University of South Carolina |
2012-09-27 | PHASE2 |
| NCT02979899 | COMPLETED | Advanced Angiosarcoma |
Tracon Pharmaceuticals Inc. |
2017-02-13 | PHASE3 |
| NCT02575066 | TERMINATED | Sarcoma; Soft Tissue Sarcomas |
The Netherlands Cancer Institute |
2016-03-17 | PHASE2 |
| NCT01975519 | COMPLETED | Advanced Soft Tissue Sarcoma |
Tracon Pharmaceuticals Inc. |
2013-12-10 | PHASE1; PHASE2 |
| NCT01841736 | ACTIVE_NOT_RECRUITING | Foregut Neuroendocrine Tumor; Hindgut Neuroendocrine Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Neuroendocrine Tumor; Midgut Neuroendocrine Tumor G1; Neuroendocrine Tumor G2; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1 |
National Cancer Institute (NCI) |
2013-09-20 | PHASE2 |
| NCT02014636 | COMPLETED | Carcinoma, Renal Cell |
Novartis Pharmaceuticals |
2013-12-27 | PHASE1 |
| NCT02009449 | COMPLETED | Melanoma; Prostate Cancer; Ovarian Cancer; Renal Cell Carcinoma; Colorectal Carcinoma; Pancreatic Carcinoma; Non-small Cell Lung Carcinoma; Solid Tumors; Breast Cancer |
Eli Lilly and Company |
2013-11-15 | PHASE1 |
| NCT01767636 | COMPLETED | Carcinoma of the Collecting Ducts of Bellini; Chromophobe Renal Cell Carcinoma; Kidney Medullary Carcinoma; Kidney Oncocytoma; Metastatic Renal Cell Cancer; Papillary Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage IV Renal Cell Cancer |
Mayo Clinic |
2013-05-16 | PHASE2 |
| NCT01462630 | COMPLETED | Adult Angiosarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma |
Fox Chase Cancer Center |
2011-11-03 | PHASE2 |
| NCT01446809 | COMPLETED | Stage IIA Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma |
University of Washington |
2012-04 | |
| NCT01813136 | COMPLETED | Thyroid Carcinoma |
Centre Leon Berard |
2013-03 | PHASE2 |
| NCT00625846 | COMPLETED | Recurrent Thyroid Gland Carcinoma; Stage III Differentiated Thyroid Gland Carcinoma AJCC v7; Stage III Thyroid Gland Medullary Carcinoma AJCC v7; Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7; Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7; Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7; Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7; Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7; Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7; Thyroid Gland Anaplastic Carcinoma |
National Cancer Institute (NCI) |
2008-02-22 | PHASE2 |
| NCT02601209 | TERMINATED | High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Metastatic Unresectable Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8; Stage IV Uterine Corpus Leiomyosarcoma AJCC v8; Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8; Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8; Unresectable Leiomyosarcoma |
National Cancer Institute (NCI) |
2015-11-30 | PHASE1; PHASE2 |
| NCT02570789 | TERMINATED | Clear-cell Metastatic Renal Cell Carcinoma |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
2012-12 | PHASE4 |
| NCT03735758 | Terminated | Soft Tissue Sarcoma Adult |
GWT-TUD GmbH |
2018-11-02 | Phase 4 |
| NCT02138526 | COMPLETED | Cancer |
Radboud University Medical Center |
2014-06 | PHASE1 |
| NCT02535351 | TERMINATED | Clear-cell Metastatic Renal Cell Carcinoma |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2015-11 | PHASE3 |
| NCT01855724 | TERMINATED | Cholangiocarcinoma; Gallbladder Carcinoma; Biliary Carcinoma |
Hellenic Cooperative Oncology Group |
2013-06-28 | PHASE2 |
| NCT03260894 | COMPLETED | Renal Cell Carcinoma (RCC) |
Incyte Corporation |
2017-12-07 | PHASE3 |
| NCT01465659 | COMPLETED | Pancreatic Alpha Cell Carcinoma; Pancreatic Beta Islet Cell Carcinoma; Pancreatic Delta Cell Carcinoma; Pancreatic G-cell Carcinoma; Recurrent Islet Cell Carcinoma |
Northwestern University |
2011-12-12 | PHASE1; PHASE2 |
| NCT01575548 | ACTIVE_NOT_RECRUITING | Clear Cell Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v7 |
National Cancer Institute (NCI) |
2012-08-08 | PHASE3 |
| NCT03275558 | WITHDRAWN | Recurrent Glioblastoma; Gliosarcoma; Anaplastic Gliomas |
Center Trials & Treatment |
2018-07-17 | PHASE1 |
| NCT01610206 | COMPLETED | Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer |
Linda R Duska |
2012-09 | PHASE2 |
| NCT02367651 | WITHDRAWN | Sarcoma, Soft Tissue |
GlaxoSmithKline |
2015-06 | PHASE2 |
| NCT02357810 | COMPLETED | Adult Liposarcoma; Metastatic Liposarcoma; Metastatic Osteosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Liposarcoma; Recurrent Osteosarcoma; Stage IV Adult Soft Tissue Sarcoma |
Northwestern University |
2015-03-21 | PHASE2 |
| NCT01876082 | COMPLETED | Progressive Desmoids Tumors |
Institut Bergonié |
2012-09-18 | PHASE2 |
| NCT01692496 | COMPLETED | Advanced and / or Metastatic Liposarcoma |
Grupo Espanol de Investigacion en Sarcomas |
2013-01-29 | PHASE2 |
| NCT01442662 | COMPLETED | Leiomyosarcoma |
UNICANCER |
2011-09 | PHASE2 |
| NCT01107665 | COMPLETED | Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma |
University of California, Irvine |
2010-08 | PHASE2 |
| NCT02208128 | UNKNOWN | Renal Cell Carcinoma |
Heidelberg University |
2014-05 | |
| NCT01330966 | COMPLETED | Chondrosarcoma; Metastatic Chondrosarcoma |
Emerald Clinical Inc. |
2011-04 | PHASE2 |
| NCT03379012 | COMPLETED | Metastatic Renal Cell Carcinoma |
Kidney Cancer Research Bureau |
2016-02-08 | PHASE2 |
| NCT01468909 | COMPLETED | Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
National Cancer Institute (NCI) |
2011-12-12 | PHASE2 |
| NCT02691767 | COMPLETED | Refractory Solid Tumors |
Samsung Medical Center |
2016-05 | |
| NCT01636908 | COMPLETED | Cancer; Advanced Solid Tumors |
Amsterdam UMC, location VUmc |
2011-08 | |
| NCT02378142 | WITHDRAWN | Uterine Leiomyosarcoma |
Gynecologic Oncology Group |
2015-03 | PHASE2 |
| NCT01503372 | COMPLETED | Advanced Gastric Cancer |
Charite University, Berlin, Germany |
2011-11 | PHASE2 |
| NCT02406521 | COMPLETED | Metastatic Renal Cell Carcinoma |
Dana-Farber Cancer Institute |
2015-04 | PHASE1 |
| NCT02055690 | TERMINATED | Ovarian Neoplasms; Neoplasms, Ovarian; Ovarian Cancer |
The Christie NHS Foundation Trust |
2014-09 | PHASE1; PHASE2 |
| NCT02122003 | TERMINATED | Metastatic Renal Cell Carcinoma |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2016-09 | PHASE2 |
| NCT01642017 | TERMINATED | Metastatic Cancer (Different Solid Tumour Types) |
Institut Claudius Regaud |
2012-11-22 | PHASE1 |
| NCT02729194 | COMPLETED | Carcinoma, Renal Cell |
University of Michigan Rogel Cancer Center |
2016-06 | EARLY_PHASE1 |
| NCT02810756 | COMPLETED | Pharmacokinetics of Pazopanib |
The Netherlands Cancer Institute |
2016-09-15 | EARLY_PHASE1 |
| NCT03149120 | WITHDRAWN | Soft Tissue Sarcomas |
NYU Langone Health |
2017-08 | PHASE2 |
| NCT02450136 | COMPLETED | Refractory Solid Tumors |
Samsung Medical Center |
2015-10-08 | |
| NCT02560012 | TERMINATED | Carcinoma, Renal Cell |
The University of Texas Health Science Center, Houston |
2016-01-04 | PHASE2 |
| NCT01861951 | COMPLETED | Soft Tissue Sarcoma |
Hannover Medical School |
2012-10 | PHASE2 |
| NCT01521715 | COMPLETED | Locally Advanced and/or Metastatic Renal Cell Carcinoma; Carcinoma, Renal Cell; Clear-cell Metastatic Renal Cell Carcinoma |
iOMEDICO AG |
2012-01-24 | PHASE4 |
| NCT01339871 | COMPLETED | Advanced Cancer |
M.D. Anderson Cancer Center |
2011-04-20 | PHASE1 |
| NCT02049905 | COMPLETED | Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma |
ImmunityBio, Inc. |
2014-01 | PHASE3 |
| NCT01600573 | UNKNOWN | Ovarian Cancer |
JSehouli |
2012-05 | PHASE1; PHASE2 |
| NCT01184326 | COMPLETED | Solid Tumor; Kidney Cancer |
Dana-Farber Cancer Institute |
2011-01 | PHASE1 |
| NCT04462445 | COMPLETED | Metastatic Renal Cell Carcinoma |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2015-06-25 | PHASE2 |
| NCT01832259 | COMPLETED | Adenocarcinoma of the Prostate |
University of Utah |
2013-08 | PHASE2 |
| NCT01797874 | COMPLETED | SCLC |
Samsung Medical Center |
2013-06 | PHASE2 |
| NCT01759303 | TERMINATED | Osteosarcoma; Metastatic Osteosarcoma |
Emerald Clinical Inc. |
2013-04 | PHASE2 |
| NCT02795819 | TERMINATED | Renal Cell Carcinoma; Soft Tissue Sarcoma; Metastatic Disease |
Virginia Commonwealth University |
2016-07-08 | PHASE1 |
| NCT01545817 | TERMINATED | Carcinoma, Renal Cell |
Novartis Pharmaceuticals |
2012-04-19 | PHASE2 |
| NCT01613846 | COMPLETED | Renal Cell Carcinoma |
Technical University of Munich |
2012-05 | PHASE3 |
| NCT01543802 | TERMINATED | Sarcoma, Soft-tissue |
Heidelberg University |
2013-04 | PHASE2 |
| NCT02279576 | TERMINATED | Penile Squamous Cell Carcinoma Stage IV |
Spanish Oncology Genito-Urinary Group |
2015-01 | PHASE2 |
| NCT02113826 | TERMINATED | Metastatic Alveolar Soft Part Sarcoma |
Seoul National University Hospital |
2014-04 | PHASE2 |
| NCT01713972 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
Manisha Shah |
2012-11-19 | PHASE1 |
| NCT02207309 | TERMINATED | Sarcoma |
Ludwig-Maximilians - University of Munich |
2015-06-22 | PHASE2 |
| NCT01639911 | COMPLETED | Malignant Neoplasm of Breast; CNS Malignancy; Malignant Neoplasm of Gastrointestinal Tract; Genitourinary Neoplasms Malignancy and Gender Unspecified; Head and Neck Neoplasms; Melanoma; Malignant Neoplasm of Thorax |
University of Illinois at Chicago |
2013-08-14 | PHASE1 |
| NCT01743482 | COMPLETED | Germ Cell Tumors; Measurable Disease |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2013-05-17 | PHASE2 |
| NCT01514448 | COMPLETED | Metastatic Renal Cell Carcinoma (mRCC) |
Novartis Pharmaceuticals |
2012-05-21 | PHASE4 |
| NCT01438554 | COMPLETED | Solid Tumors; Thyroid Cancer; Soft-tissue Sarcoma; Cholangiocarcinoma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2011-10 | PHASE1 |
| NCT01961583 | TERMINATED | Kidney Neoplasm |
Asan Medical Center |
2013-09 | PHASE2 |
| NCT01407562 | TERMINATED | Unspecified Adult Solid Tumor - Protocol Specific; Breast Cancer - Female |
Rutgers, The State University of New Jersey |
2010-09-17 | PHASE1 |
| NCT02089802 | TERMINATED | Locally Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma |
Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e. |
2014-02-25 | PHASE2 |
| NCT01361334 | COMPLETED | Acute Myeloid Leukemia |
University Hospital Muenster |
2011-06 | PHASE2 |
| NCT02204371 | TERMINATED | Telangiectasia, Hereditary Hemorrhagic |
GlaxoSmithKline |
2015-02-25 | PHASE2 |
| NCT01472081 | COMPLETED | Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma |
Bristol-Myers Squibb |
2012-02-09 | PHASE1 |
| NCT01622660 | TERMINATED | Bladder Cancer |
Memorial Sloan Kettering Cancer Center |
2012-06 | PHASE2 |
| NCT01247571 | COMPLETED | Recurrent Uterine Corpus Sarcoma; Uterine Carcinosarcoma |
National Cancer Institute (NCI) |
2011-01 | PHASE2 |
| NCT01158521 | COMPLETED | Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer |
Case Comprehensive Cancer Center |
2010-06 | PHASE2 |
| NCT02393820 | COMPLETED | Salivary Gland Carcinoma |
UNICANCER |
2013-08-26 | PHASE2 |
| NCT01552356 | ACTIVE_NOT_RECRUITING | Solid Neoplasm |
National Cancer Institute (NCI) |
2012-03-19 | PHASE1 |
| NCT01466972 | COMPLETED | Breast Cancer; Breast Neoplasm |
Hope Rugo, MD |
2012-04-27 | PHASE2 |
| NCT01599832 | TERMINATED | Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer |
University of Chicago |
2012-06 | |
| NCT02324803 | UNKNOWN | Self Efficacy; Adverse Drug Event; Carcinoma, Renal Cell |
Southern China Urology Cancer Consortium |
2014-07 | PHASE2 |
| NCT01513187 | COMPLETED | Advanced Renal Cell Carcinoma |
Spanish Oncology Genito-Urinary Group |
2011-07-11 | PHASE1; PHASE2 |
| NCT00775307 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Intergroupe Francophone de Cancerologie Thoracique |
2008-11 | PHASE2; PHASE3 |
| NCT01418001 | TERMINATED | Sarcoma; Leiomyosarcoma; Malignant Peripheral Nerve Sheath Tumor; Malignant Fibrous; Histiocytoma/Undifferentiated Pleomorphic Sarcoma |
Memorial Sloan Kettering Cancer Center |
2011-08 | PHASE1; PHASE2 |
| NCT01235962 | COMPLETED | Renal Cell Carcinoma (RCC); Cancer |
Novartis Pharmaceuticals |
2010-11-30 | PHASE3 |
| NCT02307474 | WITHDRAWN | Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma |
Case Comprehensive Cancer Center |
2015-09 | |
| NCT00486642 | COMPLETED | Hormone-Resistant Prostate Cancer; Recurrent Prostate Carcinoma |
National Cancer Institute (NCI) |
2007-09 | PHASE2 |
| NCT01716416 | COMPLETED | Squamous Cell Carcinoma of the Head and Neck |
Washington University School of Medicine |
2013-05-31 | PHASE1 |
| NCT01385228 | COMPLETED | Prostate Cancer |
Daniel George, MD |
2011-06 | PHASE1 |
| NCT01221506 | COMPLETED | Carcinoma, Renal Cell |
Abramson Cancer Center at Penn Medicine |
2010-10 | EARLY_PHASE1 |
| NCT01130805 | COMPLETED | Gastric Cancer |
Samsung Medical Center |
2010-12 | PHASE2 |
| NCT01208064 | TERMINATED | Lung Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2011-07 | PHASE2; PHASE3 |
| NCT00800345 | COMPLETED | Gynecologic Tumors |
Vector Oncology |
2009-04 | PHASE1 |
| NCT01608009 | COMPLETED | Ovarian Neoplasm |
Imperial College London |
2012-07 | PHASE1 |
| NCT01719302 | COMPLETED | Stage III Adult Soft Tissue Sarcoma |
University of Vermont |
2012-10 | PHASE1; PHASE2 |
| NCT01713296 | COMPLETED | SCLC |
Hellenic Oncology Research Group |
2011-11 | PHASE2 |
| NCT01454804 | COMPLETED | Advanced Cancers |
M.D. Anderson Cancer Center |
2011-10 | PHASE1 |
| NCT01538238 | COMPLETED | Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma |
Samsung Medical Center |
2012-05-02 | PHASE2 |
| NCT01361113 | COMPLETED | Renal Cell Carcinoma |
UNC Lineberger Comprehensive Cancer Center |
2011-06 | PHASE2 |
| NCT01524848 | COMPLETED | Gastrointestinal Stromal Tumors |
Scandinavian Sarcoma Group |
2012-02 | PHASE2 |
| NCT01716546 | TERMINATED | Gastric Cancer |
Hellenic Oncology Research Group |
2011-07 | PHASE1; PHASE2 |
| NCT01108055 | COMPLETED | Bladder Cancer; Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive); Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy); Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable |
Sandy Srinivas |
2010-04 | PHASE2 |
| NCT01340794 | TERMINATED | Extra-Adrenal Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma; Paraganglioma; Recurrent Adrenal Gland Pheochromocytoma |
National Cancer Institute (NCI) |
2011-05 | PHASE2 |
| NCT01238770 | COMPLETED | Epithelial Ovarian Cancer |
Priv.-Doz. Dr. med. Joachim Rom |
2010-11 | PHASE1; PHASE2 |
| NCT01577784 | UNKNOWN | Metastatic Renal Cell Carcinoma |
Associació per a la Recerca Oncologica, Spain |
2012-04 | PHASE2 |
| NCT01666418 | COMPLETED | Melanoma |
University of Zurich |
2012-08 | PHASE2 |
| NCT01506596 | COMPLETED | Liposarcoma; Surgically Unresectable Liposarcoma; Metastatic Liposarcoma |
Vector Oncology |
2012-03 | PHASE2 |
| NCT01468922 | COMPLETED | Solid Tumor |
National Cancer Institute (NCI) |
2012-01-23 | PHASE1 |
| NCT01392352 | TERMINATED | Renal Cell Carcinoma; Soft Tissue Sarcoma; Glioblastoma; Ovarian Cancer; Cervical Cancer; Breast Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Pancreatic Cancer; Melanoma; Gastrointestinal Cancer |
Cambridge University Hospitals NHS Foundation Trust |
2011-04 | PHASE2 |
| NCT01262820 | COMPLETED | Lung Cancer |
UNC Lineberger Comprehensive Cancer Center |
2010-12 | PHASE2 |
| NCT01985295 | COMPLETED | Sarcoma,Soft Tissue |
The Netherlands Cancer Institute |
2010-06 | PHASE1 |
| NCT01644825 | COMPLETED | Ovarian Cancer |
National Cancer Institute, Naples |
2010-12 | PHASE2 |
| NCT01027598 | COMPLETED | Non Small Cell Lung Cancer |
SCRI Development Innovations, LLC |
2010-01 | PHASE2 |
| NCT01323400 | COMPLETED | GIST |
Centre Leon Berard |
2011-03 | PHASE2 |
| NCT01408004 | COMPLETED | Clear Cell Renal Carcinoma |
Netherlands Working Group on Immunotherapy of Oncology |
2011-11 | PHASE2 |
| NCT01059656 | TERMINATED | Dermatofibrosarcomas of DARIER FERRAND(DFSP) |
Assistance Publique - Hôpitaux de Paris |
2010-07 | PHASE2 |
| NCT00454363 | COMPLETED | Gastrin-Producing Neuroendocrine Tumor; Lung Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Multiple Endocrine Neoplasia Type 1; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Recurrent Pancreatic Neuroendocrine Carcinoma; Regional Digestive System Neuroendocrine Tumor G1; Somatostatin-Producing Neuroendocrine Tumor |
National Cancer Institute (NCI) |
2007-03 | PHASE2 |
| NCT01049776 | TERMINATED | Non Small Cell Lung Cancer |
Illinois CancerCare, P.C. |
2010-01 | PHASE2 |
| NCT01262014 | COMPLETED | Platinum-resistant Advanced Ovarian Cancer |
Grupo Español de Investigación en Cáncer de Ovario |
2010-12 | PHASE2 |
| NCT00297258 | COMPLETED | Sarcoma, Soft Tissue |
GlaxoSmithKline |
2005-11 | PHASE2 |
| NCT00992121 | COMPLETED | Carcinoma, Renal Cell |
GlaxoSmithKline |
2009-11-18 | PHASE1 |
| NCT01413113 | COMPLETED | Recurrent Thyroid Cancer; Stage IVA Follicular Thyroid Cancer; Stage IVA Papillary Thyroid Cancer; Stage IVB Follicular Thyroid Cancer; Stage IVB Papillary Thyroid Cancer; Stage IVC Follicular Thyroid Cancer; Stage IVC Papillary Thyroid Cancer |
University of Washington |
2011-12 | PHASE1 |
| NCT01157091 | COMPLETED | Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer |
City of Hope Medical Center |
2010-12-08 | PHASE2 |
| NCT01165385 | COMPLETED | Solid Tumors; Metastatic Cancer |
UNICANCER |
2010-06 | PHASE1 |
| NCT00732420 | COMPLETED | Solid Tumours |
GlaxoSmithKline |
2008-09-24 | PHASE1 |
| NCT01391611 | TERMINATED | Gastrointestinal Stromal Tumor (GIST) |
Kristen Ganjoo |
2011-07 | PHASE2 |
| NCT01377298 | UNKNOWN | Head and Neck Squamous Cell Carcinoma |
National Taiwan University Hospital |
2011-06 | PHASE2 |
| NCT00929903 | COMPLETED | Childhood Central Nervous System Choriocarcinoma; Childhood Central Nervous System Embryonal Tumor; Childhood Central Nervous System Germ Cell Tumor; Childhood Central Nervous System Germinoma; Childhood Central Nervous System Mixed Germ Cell Tumor; Childhood Central Nervous System Teratoma; Childhood Central Nervous System Yolk Sac Tumor; Metastatic Childhood Soft Tissue Sarcoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Central Nervous System Embryonal Tumor; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Childhood Visual Pathway Glioma; Unspecified Childhood Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2009-06 | PHASE1 |
| NCT01280201 | COMPLETED | Advanced/Metastatic Neuroendocrine Tumors |
Grupo Espanol de Tumores Neuroendocrinos |
2011-01-26 | PHASE2 |
| NCT00387205 | COMPLETED | Carcinoma, Renal Cell |
Novartis Pharmaceuticals |
2006-06-20 | PHASE1 |
| NCT01485042 | COMPLETED | Solid Tumors |
Herbert Hurwitz, MD |
2011-12 | PHASE1 |
| NCT01012362 | TERMINATED | Breast Cancer; Lung Cancer; Colon Cancer; Pancreatic Cancer; Head and Neck Cancer; Kidney Cancer; Sarcoma; Hepatocellular Cancer |
Masonic Cancer Center, University of Minnesota |
2009-12 | PHASE1 |
| NCT01542047 | TERMINATED | Cancer, Metastatic |
New Mexico Cancer Research Alliance |
2012-08 | PHASE1 |
| NCT00674024 | COMPLETED | Neoplasms; Lymphoma |
National Cancer Institute (NCI) |
2008-10-07 | PHASE1 |
| NCT01202032 | COMPLETED | Metastatic Renal Cell Carcinoma; Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed |
Centre Leon Berard |
2010-07 | PHASE1 |
| NCT00615524 | WITHDRAWN | Hormone-receptor Positive Breast Cancer |
GlaxoSmithKline |
2008-04 | PHASE2 |
| NCT00866528 | COMPLETED | Lung Cancer, Non-Small Cell |
GlaxoSmithKline |
2009-07-09 | PHASE1 |
| NCT01134055 | COMPLETED | Macular Degeneration |
GlaxoSmithKline |
2010-06-01 | PHASE2 |
| NCT01179269 | WITHDRAWN | Non-small Cell Lung Cancer |
Loyola University |
2010-03 | PHASE2 |
| NCT00945477 | TERMINATED | Prostate Cancer |
Illinois CancerCare, P.C. |
2009-07 | PHASE2 |
| NCT01227928 | COMPLETED | Neoplasms, Ovarian |
GlaxoSmithKline |
2010-09 | PHASE2 |
| NCT01253369 | COMPLETED | Small Cell Lung Cancer; Lung Cancer; SCLC |
Dana-Farber Cancer Institute |
2010-06 | PHASE2 |
| NCT00866697 | COMPLETED | Ovarian Cancer |
Novartis Pharmaceuticals |
2009-05-26 | PHASE3 |
| NCT01313663 | TERMINATED | Lung Cancer, Small Cell |
GlaxoSmithKline |
2011-02 | PHASE2 |
| NCT00722293 | COMPLETED | Neoplasms, Breast |
GlaxoSmithKline |
2008-07-08 | PHASE1 |
| NCT01035658 | TERMINATED | Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Carcinoma |
SCRI Development Innovations, LLC |
2010-01 | PHASE1; PHASE2 |
| NCT01147822 | COMPLETED | Carcinoma, Renal Cell |
Novartis Pharmaceuticals |
2010-05-19 | PHASE2 |
| NCT00720941 | COMPLETED | Carcinoma, Renal Cell |
Novartis Pharmaceuticals |
2008-08-14 | PHASE3 |
| NCT01362348 | TERMINATED | Macular Degeneration |
GlaxoSmithKline |
2011-07-07 | PHASE2 |
| NCT01394211 | TERMINATED | Estrogen Receptor-positive Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Male Breast Cancer; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer |
University of Arizona |
2011-07-13 | PHASE2 |
| NCT01099540 | COMPLETED | Neuroendocrine Tumor |
Samsung Medical Center |
2010-04 | PHASE2 |
| NCT01072890 | COMPLETED | Solid Tumors |
University of California, Davis |
2010-02 | PHASE1 |
| NCT01060514 | TERMINATED | Metastatic Non Small Cell Lung Cancer; Metastatic Breast Cancer |
Northwestern University |
2010-02 | PHASE1 |
| NCT01265940 | COMPLETED | Advanced Urothelial Cancer of Bladder After Failure of Platinum-containing Therapy. |
Prof. Dr. Thomas Otto |
2011-03 | PHASE1; PHASE2 |
| NCT01257750 | COMPLETED | Corneal Neovascularization |
Reza Dana, MD |
2010-11 | PHASE1; PHASE2 |
| NCT01498458 | COMPLETED | Metastatic Breast Cancer |
GBG Forschungs GmbH |
2010-10 | PHASE1 |
| NCT01031875 | COMPLETED | Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2009-12 | PHASE2 |
| NCT00849472 | COMPLETED | Neoplasms, Breast |
GlaxoSmithKline |
2009-07 | PHASE2 |
| NCT01130623 | WITHDRAWN | Sarcoma; Neuroblastoma; Wilms Tumor; Osteosarcoma; Brain Tumor |
National Cancer Institute (NCI) |
2010-05-10 | PHASE1 |
| NCT01064310 | COMPLETED | Carcinoma, Renal Cell |
Novartis Pharmaceuticals |
2010-05-17 | PHASE3 |
| NCT01205230 | COMPLETED | Cancer |
GlaxoSmithKline |
2010-09 | PHASE4 |
| NCT00731211 | COMPLETED | Renal Cell Carcinoma |
SCRI Development Innovations, LLC |
2008-09 | PHASE2 |
| NCT00558103 | COMPLETED | Neoplasms, Breast |
GlaxoSmithKline |
2007-12 | PHASE2 |
| NCT01154062 | COMPLETED | Macular Degeneration |
GlaxoSmithKline |
2010-08-16 | PHASE1 |
| NCT00871403 | COMPLETED | Lung Cancer, Non-Small Cell |
GlaxoSmithKline |
2009-07 | PHASE2 |
| NCT00454571 | COMPLETED | Recurrent Prostate Cancer |
National Cancer Institute (NCI) |
2006-06 | PHASE2 |
| NCT01080248 | TERMINATED | Pancreatic Cancer |
Washington University School of Medicine |
2010-08 | PHASE2 |
| NCT00753688 | COMPLETED | Sarcoma, Soft Tissue |
GlaxoSmithKline |
2008-10 | PHASE3 |
| NCT00450879 | TERMINATED | Male Breast Carcinoma; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer |
National Cancer Institute (NCI) |
2007-01 | PHASE1 |
| NCT00861913 | COMPLETED | Recurrent Melanoma; Stage IV Cutaneous Melanoma AJCC v6 and v7 |
National Cancer Institute (NCI) |
2009-04-03 | PHASE2 |
| NCT00516672 | COMPLETED | Carcinoma, Renal Cell |
GlaxoSmithKline |
2007-09-10 | PHASE1 |
| NCT00471536 | COMPLETED | Distal Urethral Cancer; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer |
National Cancer Institute (NCI) |
2008-08 | PHASE2 |
| NCT00827372 | COMPLETED | Lymphedema |
Kathy Miller |
2009-01 | PHASE2 |
| NCT01072214 | COMPLETED | Macular Degeneration |
GlaxoSmithKline |
2010-03-09 | PHASE1 |
| NCT01051700 | COMPLETED | Macular Degeneration |
GlaxoSmithKline |
2010-01-12 | PHASE1 |
| NCT00540943 | COMPLETED | Neoplasms, Colorectal |
GlaxoSmithKline |
2007-07-13 | PHASE1 |
| NCT00454142 | COMPLETED | Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx |
National Cancer Institute (NCI) |
2007-08 | PHASE2 |
| NCT00678977 | COMPLETED | Lung Cancer, Non-Small Cell |
GlaxoSmithKline |
2008-04-03 | PHASE1 |
| NCT00861029 | COMPLETED | Carcinoma, Renal Cell |
GlaxoSmithKline |
2009-03-19 | PHASE1 |
| NCT00387764 | COMPLETED | Carcinoma, Renal Cell |
GlaxoSmithKline |
2006-09 | PHASE3 |
| NCT00350727 | COMPLETED | Glioma |
GlaxoSmithKline |
2006-12 | PHASE2 |
| NCT00733304 | COMPLETED | Macular Degeneration |
GlaxoSmithKline |
2008-06-25 | PHASE2 |
| NCT00619424 | COMPLETED | Lung Cancer, Non-Small Cell |
GlaxoSmithKline |
2007-11-15 | PHASE1 |
| NCT00387387 | COMPLETED | Neoplasms, Colorectal |
GlaxoSmithKline |
2006-10-20 | PHASE1 |
| NCT00388076 | COMPLETED | Neoplasms, Breast |
GlaxoSmithKline |
2006-04-28 | PHASE1 |
| NCT00509587 | COMPLETED | Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer |
National Cancer Institute (NCI) |
2007-06 | PHASE2 |
| NCT00363194 | COMPLETED | Carcinoma, Renal Cell |
GlaxoSmithKline |
2006-09-21 | PHASE1 |
| NCT00370513 | COMPLETED | Carcinoma, Hepatocellular |
GlaxoSmithKline |
2006-12-06 | PHASE1 |
| NCT00549328 | TERMINATED | Lung Cancer, Non-Small Cell |
GlaxoSmithKline |
2008-02 | PHASE2 |
| NCT00459862 | COMPLETED | Advanced Malignant Mesothelioma; Localized Malignant Mesothelioma; Recurrent Malignant Mesothelioma |
National Cancer Institute (NCI) |
2007-03 | PHASE2 |
| NCT00612456 | COMPLETED | Macular Degeneration |
GlaxoSmithKline |
2008-03-05 | PHASE2 |
| NCT00459381 | COMPLETED | Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor |
National Cancer Institute (NCI) |
2007-05 | PHASE2 |
| NCT00347919 | COMPLETED | Neoplasms, Breast |
GlaxoSmithKline |
2006-07 | PHASE2 |
| NCT00478725 | COMPLETED | Carcinoma, Renal Cell |
GlaxoSmithKline |
2007-07-18 | PHASE1 |
| NCT00430781 | COMPLETED | Neoplasms, Uterine Cervix; Metastatic Cervical Cancer |
GlaxoSmithKline |
2006-11 | PHASE2 |
| NCT00659555 | COMPLETED | Macular Degeneration |
GlaxoSmithKline |
2008-04-04 | PHASE1 |
| NCT00334282 | COMPLETED | Carcinoma, Renal Cell |
GlaxoSmithKline |
2006-04 | PHASE3 |
| NCT00367679 | COMPLETED | Non-Small Cell Lung Cancer; Lung Cancer, Non-Small Cell |
GlaxoSmithKline |
2006-11 | PHASE2 |
| NCT00561795 | COMPLETED | Primary Peritoneal Carcinoma; Tumor; Epithelial Ovarian Cancer; Uterine Disease; Cervix Diseases; Neoplasms, Ovarian; Cancer |
GlaxoSmithKline |
2007-09 | PHASE2 |
| NCT00401583 | COMPLETED | Carcinoma, Renal Cell |
GlaxoSmithKline |
2006-07-28 | PHASE1 |
| NCT00358384 | COMPLETED | Psoriasis |
GlaxoSmithKline |
2005-09-26 | PHASE1 |
| NCT00463320 | COMPLETED | Macular Degeneration; Age-related Macular Degeneration |
GlaxoSmithKline |
2007-03 | PHASE1 |
| NCT00060151 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
Case Comprehensive Cancer Center |
2002-12 | PHASE1 |
| NCT00256880 | COMPLETED | Carcinoma, Renal Cell |
GlaxoSmithKline |
2005-01 | PHASE2 |
| NCT00788580 | WITHDRAWN | Unspecified Adult Solid Tumor, Protocol Specific |
SWOG Cancer Research Network |
PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-08-03)
Check the
Pazopanib HCl
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.